Top

Published in:

01-10-2012 | Review Article

Current and Emerging Systemic Treatment Strategies for Psoriasis

Authors: Philip M. Laws, Dr Helen S. Young

Published in: Drugs | Issue 14/2012

Abstract

Psoriasis is a common chronic inflammatory disease of the skin that has a significant impact on quality of life. A small number of systemic therapies are well established in psoriasis management. These have immunosuppressive and/or anti-proliferative effects on the skin and immune system. As understanding of the pathogenesis of psoriasis has advanced over the last 2 decades, there has been clearer appreciation of the genetic, cellular and immunological components of disease expression, which has provided new insight into potential therapeutic targets, including the development of biological therapies. Biologics offer a unique opportunity to block or inhibit specific key components of psoriasis pathogenesis. The introduction of tumour necrosis factor (TNF)-α and interleukin (IL)-12/-23 inhibitors has resulted in remarkable clinical responses in patients with severe psoriasis and has led to the development of a range of other cytokine modulators currently undergoing investigation. More recently, research in keratinocyte biology and immune cell function, particularly intracellular signalling, has afforded additional opportunities to develop a range of small-molecule oral preparations that may prove effective in disease control. This paper reviews current and emerging systemic treatments in the management of psoriasis.

Griffiths CEM, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007 Jul 21; 370 (9583): 263–71PubMedCrossRef

Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985 Sep; 13 (3): 450–6PubMedCrossRef

Bowcock AM, Cookson WO. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet 2004 Apr 1; 13 Spec No. 1: R43-55

Griffiths CEM, Christophers E, Barker JN, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007 Feb; 156 (2): 258–62PubMedCrossRef

de Korte J, Sprangers MA, Mombers FM, et al. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004 Mar; 9 (2): 140–7PubMedCrossRef

Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br JDermatol 1998 Nov; 139 (5): 846–50CrossRef

Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 Sep; 41 (3 Pt 1): 401–7PubMedCrossRef

Gladmann DD. Psoriatic Arthritis. In: Harris ED, Budd RC, Firestein GS, et al. Editors. Kelly’s textbook of rheumatology, 7th ed. Philadelphia (PA): WB Saunders, 2004: 1155–64

Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol 2011 Nov; 165 (5): 1037–43PubMedCrossRef

10.

Laws PM, Young HS. Topical treatment of psoriasis. Expert Opin Pharmacother 2010 Aug; 11 (12): 1999–2009PubMedCrossRef

11.

Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010 Jan; 62 (1): 114–35

12.

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 May; 19 (3): 210–6PubMedCrossRef

13.

Sandhu K, Kaur I, Kumar B, et al. Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India. J Dermatol 2003 Jun; 30 (6): 458–63PubMed

14.

Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003 Aug 14; 349 (7): 658–65PubMedCrossRef

15.

Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011 Nov; 165 (5): 1109–17PubMed

16.

Flytstrom I, Stenberg B, Svensson A, et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008 Jan; 158 (1): 116–21

17.

Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008 Mar; 158 (3): 558–66PubMed

18.

Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011 Oct 27; 365 (17): 1586–96PubMedCrossRef

19.

Guenther L, Langley RG, Shear NH, et al. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004. J Cutan Med Surg 2004 Sep–Oct; 8 (5): 321–37CrossRef

20.

Roenigk Jr HH, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998 Mar; 38 (3): 478–85PubMedCrossRef

21.

Chalmers RJ, Kirby B, Smith A, et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005 Mar; 152 (3): 444–50PubMedCrossRef

22.

Berends MA, Snoek J, de Jong EM, et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int 2007 Jun; 27 (5): 639–45PubMedCrossRef

23.

Barker J, Horn EJ, Lebwohl M, et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol 2011 Jul; 25 (7): 758–64PubMedCrossRef

24.

Gottlieb AB, Grossman RM, Khandke L, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol 1992 Mar; 98 (3): 302–9PubMedCrossRef

25.

Fry L, Griffiths CE, Powles AV, et al. Long-term cyclosporine in the management of psoriasis. Transplant Proc 1988 Jun; 20 (3 Suppl. 4): 23-5

26.

Ho VC, Griffiths CE, Berth-Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001 Apr; 44 (4): 643–51PubMedCrossRef

27.

Ho VC, Griffiths CE, Albrecht G, et al. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol 1999 Aug; 141 (2): 283–91CrossRef

28.

Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol 1998 Jul; 139 (1): 88–95CrossRef

29.

Thaci D, Brautigam M, Kaufmann R, et al. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis: a randomised study. Dermatology 2002; 205 (4): 383–8PubMedCrossRef

30.

Reitamo S, Spuls P, Sassolas B, et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a sub-therapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001 Sep; 145 (3): 438–45PubMedCrossRef

31.

Griffiths CEM, Dubertret L, Ellis CN, et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004 May; 150 Suppl. 67: 11–23PubMedCrossRef

32.

Shupack J, Abel E, Bauer E, et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol 1997 Mar; 36 (3 Pt 1): 423–32PubMedCrossRef

33.

Mrowietz U, Farber L, Henneicke-von Zepelin HH, et al. Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study. German Multicenter Study. J Am Acad Dermatol 1995 Sep; 33 (3): 470–5CrossRef

34.

Schulze HJ, Mahrle G, Steigleder GK. Topical cyclosporin A in psoriasis. Br J Dermatol 1990 Jan; 122 (1): 113–4PubMedCrossRef

35.

Heule F, Laijendecker R, van Joost T. Topical cyclosporin A treatment in psoriasis and other dermatological diseases: theoretical and practical aspects. J Dermatologl Treat 1992; 2 (4): 149–53CrossRef

36.

Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157 (4): 238–44PubMedCrossRef

37.

Gollnick H, Bauer R, Brindley C, et al. Acitretin versus etretinate in psoriasis: clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol 1988 Sep; 19 (3): 458–68PubMedCrossRef

38.

Van Zander J, Orlow SJ. Efficacy and safety of oral retinoids in psoriasis. Expert Opin Drug Saf 2005 Jan; 4 (1): 129–38PubMedCrossRef

39.

Buccheri L, Katchen BR, Karter AJ, et al. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol 1997 Jun; 133 (6): 711–5PubMedCrossRef

40.

Tanew A, Guggenbichler A, Honigsmann H, et al. Photo-chemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991 Oct; 25 (4): 682–4PubMedCrossRef

41.

Lebwohl M, Drake L, Menter A, et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001 Oct; 45 (4): 544–53PubMedCrossRef

42.

Berth-Jones J, Todd G, Hutchinson PE, et al. Treatment of psoriasis with oral liarozole: a dose-ranging study. Br J Dermatol 2000 Dec; 143 (6): 1170–6PubMedCrossRef

43.

Bhushan M, Burden AD, McElhone K, et al. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2001 Oct; 145 (4): 546–53PubMedCrossRef

44.

Schweckendiek W. Treatment of psoriasis vulgaris. Med Monatsschr 1959 Feb; 13 (2): 103–4PubMed

45.

Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 2007 Jun; 299 (3): 111–38PubMedCrossRef

46.

Treumer F, Zhu K, Glaser R, et al. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003 Dec; 121 (6): 1383–8PubMedCrossRef

47.

Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 1998 Mar; 138 (3): 456–60CrossRef

48.

Harries MJ, Chalmers RJ, Griffiths CE. Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. Br J Dermatol 2005 Sep; 153 (3): 549–51PubMedCrossRef

49.

Hoefnagel JJ, Thio HB, Willemze R, et al. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003 Aug; 149 (2): 363–9PubMedCrossRef

50.

Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009 Jul 30; 361 (5): 496–509PubMedCrossRef

51.

Yamauchi PS, Gindi V, Lowe NJ. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. Dermatol Clin 2004 Oct; 22 (4): 449–59, ixPubMedCrossRef

52.

Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J. Am. Acad. Dermatol 2008 May; 58 (5): 851–64

53.

Krueger GG, Elewski B, Papp K, et al. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. J Am Acad Dermatol 2006 Mar; 54 (3 Suppl. 2): S1 12-9

54.

Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007 Apr; 56 (4): 598–603PubMedCrossRef

55.

Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005 Jun; 152 (6): 1304–12PubMedCrossRef

56.

Strober BE, Crowley JJ, Yamauchi PS, et al. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011 Sep; 165 (3): 661–8PubMedCrossRef

57.

Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008 Jan 17; 358 (3): 241–51PubMedCrossRef

58.

Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 Oct 15–21; 366 (9494): 1367–74PubMedCrossRef

59.

Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007 Jan; 56 (1): 31 e1-15

60.

Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006 Jun; 154 (6): 1161–8PubMedCrossRef

61.

Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008 Jan; 58 (1): 106–15PubMedCrossRef

62.

Revicki DA, Menter A, Feldman S, et al. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled phase III study. Health Qual Life Outcomes 2008; 6: 75PubMedCrossRef

63.

Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001 Jul 26; 345 (4): 248–55PubMedCrossRef

64.

Krueger GG. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2003 Jul; 17 Suppl. 2: 17-24

65.

Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002 Dec; 47 (6): 821–33PubMedCrossRef

66.

Robertson MJ, Ritz J. Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist 1996; 1 (1 & 2): 88-97

67.

Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009 Aug 27; 361 (9): 888–98PubMedCrossRef

68.

Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008 May; 128 (5): 1064–7PubMedCrossRef

69.

Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008 May 17; 371 (9625): 1665–74PubMedCrossRef

70.

Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008 May 17; 371 (9625): 1675–84PubMedCrossRef

71.

Griffiths CEM, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010 Jan 14; 362 (2): 118–28PubMedCrossRef

72.

Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009 Feb 21; 373 (9664): 633–40PubMedCrossRef

73.

Clark CM, Kirby B, Morris AD, et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol 1999 Aug; 141 (2): 279–82PubMedCrossRef

74.

Aydin F, Canturk T, Senturk N, et al. Methotrexate and ciclosporin combination for the treatment of severe psoriasis. Clin Exp Dermatol 2006 Jul; 31 (4): 520–4PubMedCrossRef

75.

Lowenthal KE, Horn PJ, Kalb RE. Concurrent use of methotrexate and acitretin revisited. J Dermatolog Treat 2008; 19 (1): 22–6PubMedCrossRef

76.

Cather JC, Menter A. Combining traditional agents and biologics for the treatment of psoriasis. Semin Cutan Med Surg 2005 Mar; 24 (1): 37–45PubMedCrossRef

77.

Laws PM, Downs AM, Parslew R, et al. Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the UK and Ireland. Br J Dermatol 2012 Jan; 166 (1): 189–95PubMedCrossRef

78.

Ortonne JP, Reich K, Sterry W, et al. Safety and efficacy (PASI 90 and global evaluation) of subcutaneous certolizumab pegol in patients with moderate to severe chronic plaque psoriasis: Results from a double-blind, placebo-controlled trial [abstract]. J Am Acad Dermatol 2008; 58 (2 Suppl. 2): AB4

79.

Gay RD, Clarke AW, Elgundi Z, et al. Anti-TNFalpha domain antibody construct CEP-37247: full antibody functionality at half the size. MAbs 2010 Nov–Dec; 2 (6): 625–38PubMedCrossRef

80.

Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009 Apr; 60 (4): 976–86PubMedCrossRef

81.

Gordon KB, Langley RG, Gottlieb AB, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2012 Feb; 132 (2): 304–14PubMedCrossRef

82.

Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007 Feb 8; 445 (7128): 648–51PubMedCrossRef

83.

Papp K, Sigurgeirrson B, Abe M, et al. Secukinumab efficacy and safety preliminary results from a phase II subcutaneous dose-ranging study in the treatment of moderate-to-severe plaque psoriasis [oral presentation FC01.5]. Presented at 20th Congress of the European Academy of Dermatology and Venereology; 2011 Oct 20–24; Lisbon

84.

Papp K, Matheson RT, Tu JH, et al. Secukinumab, a novel fully human antibody to interleukin-17A, in the treatment of moderate-to-severe plaque psoriasis: efficacy and safety interim results from a phase II intravenous induction dose-ranging study [oral presentation FC01.7]. Presented at 20th Congress of the European Academy of Dermatology and Venereology; 2011 Oct 20–24; Lisbon

85.

Scheinfeld N. Abatacept: a review of a new biologic agent for refractory rheumatoid arthritis for dermatologists. J Dermatolog Treat 2006; 17 (4): 229–34PubMedCrossRef

86.

Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011 Apr; 63 (4): 939–48PubMedCrossRef

87.

Silverman D, Oliver A. Abatacept-induced psoriasis. Cutis 2011 Sep; 88 (3): 117–8PubMed

88.

Kato K, Satoh T, Nishizawa A, et al. Psoriasiform drug eruption due to abatacept. Acta Derm Venereol 2011 May; 91 (3): 362–3PubMedCrossRef

89.

Florent A, Albert C, Giacchero D, et al. Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathy. Joint Bone Spine 2010 Dec; 77 (6): 626–7PubMedCrossRef

90.

Branco L, Barren P, Mao SY, et al. Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. Transplantation 1999 Nov 27; 68 (10): 1588–96PubMedCrossRef

91.

Moingeon PE, Lucich JL, Stebbins CC, et al. Complementary roles for CD2 and LFA-1 adhesion pathways during T cell activation. Eur J Immunol 1991 Mar; 21 (3): 605–10PubMedCrossRef

92.

Langley RG, Papp K, Bissonnette R, et al. Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies. Int J Dermatol 2010 Jul; 49 (7): 818–28PubMed

93.

Abdelnoor AM. Patented small molecules against psoriasis. Expert Opin Ther Pat 2009 Aug; 19 (8): 1057–71PubMedCrossRef

94.

Papp K, Bissonnette R, Rosoph L, et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 2008 Apr 19; 371 (9621): 1337–42PubMedCrossRef

95.

Pesu M, Laurence A, Kishore N, et al. Therapeutic targeting of Janus kinases. Immunol Rev 2008 Jun; 223: 132–42PubMedCrossRef

96.

Vijayakrishnan L, Venkataramanan R, Gulati P. Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci 2011 Jan; 32 (1): 25–34PubMedCrossRef

97.

Boy MG, Wang C, Wilkinson BE, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol 2009 Sep; 129 (9): 2299–302PubMedCrossRef

98.

Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol 2009 Apr; 21 (2): 317–24PubMedCrossRef

99.

Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010 Apr 30; 106 (8): 1319–31PubMedCrossRef

100.

Bertram A, Ley K. Protein kinase C isoforms in neutrophil adhesion and activation. Arch Immunol Ther Exp (Warsz) 2011 Apr; 59 (2): 79–87CrossRef

101.

Skvara H, Dawid M, Kleyn E, et al. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest 2008 Sep; 118 (9): 3151–9PubMedCrossRef

102.

Castro A, Jerez MJ, Gil C, et al. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phos-phodiesterase inhibitors. Med Res Rev 2005 Mar; 25 (2): 229–44PubMedCrossRef

103.

Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008 May; 24 (5): 1529–38PubMedCrossRef

104.

Camins A, Sureda FX, Junyent F, et al. Sirtuin activators: designing molecules to extend life span. Biochim Biophys Acta 2010 Oct-Dec; 1799 (10-12): 740-9

105.

Rajendran R, Garva R, Krstic-Demonacos M, et al. Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription. J Biomed Biotechnol 2011; 2011: 368276PubMedCrossRef

106.

Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?. Drug Discov Today 2005 Feb 1; 10 (3): 197–204PubMedCrossRef

107.

Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 2008 Oct; 8 (10): 753–63PubMedCrossRef

108.

Johnson BJ, Le TT, Dobbin CA, et al. Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. J Biol Chem 2005 Feb 11; 280 (6): 4037–47PubMedCrossRef

109.

Williams B, Vanags D, Hall S, et al. Efficacy and safety of chaperonin 10 in patients with moderate to severe plaque psoriasis: evidence of utility beyond a single indication. Arch Dermatol 2008 May; 144 (5): 683–5PubMedCrossRef

110.

Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009 Sep; 61 (3): 451–85

111.

Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009 Oct; 23 Suppl. 2: 1–70PubMedCrossRef

112.

Friedewald Jr VE, Cather JC, Gordon KB, et al. The editor’s roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol 2008 Apr 15; 101 (8): 1119–26PubMedCrossRef

113.

Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 May; 58 (5): 826–50

114.

Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009 Nov; 161 (5): 987–1019PubMedCrossRef

Title: Current and Emerging Systemic Treatment Strategies for Psoriasis
Authors: Philip M. Laws
Dr Helen S. Young
Publication date: 01-10-2012
Publisher: Springer International Publishing
Published in: Drugs / Issue 14/2012
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/11634980-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Current and Emerging Systemic Treatment Strategies for Psoriasis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 14/2012

Nomegestrol Acetate/Estradiol

Interferon-Free Hepatitis C Therapy

Opioid-Induced Bowel Dysfunction

Bendamustine

Sedation for Critically Ill or Injured Adults in the Intensive Care Unit

Erratum to: Docetaxel